Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45 EUR | -0.44% | +1.35% | -39.19% |
29/05 | Truist Securities Lowers Price Target on Cytokinetics to $70 From $86, Maintains Buy Rating | MT |
28/05 | Cytokinetics Closes $500 Million Stock Offering | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-39.19% | 556.57Cr | - | ||
+11.91% | 12TCr | B+ | ||
+11.60% | 11TCr | B+ | ||
-4.68% | 2.43TCr | B+ | ||
-0.82% | 2.2TCr | B | ||
-10.12% | 1.82TCr | A- | ||
-42.12% | 1.64TCr | A- | ||
-17.47% | 1.56TCr | B | ||
+2.77% | 1.36TCr | C+ | ||
+34.58% | 1.23TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CYTK Stock
- KK3A Stock
- Ratings Cytokinetics, Incorporated